L&C BIO, a leader in human tissue regenerative medicine, is set to make its mark in the Middle East by gaining import approval for its innovative product, Re2O, in the United Arab Emirates. This development opens the door to new opportunities in a region with growing demand for advanced healthcare solutions.
Expansion Strategy into the Middle East
As part of its strategy to expand internationally, L&C BIO is keen on strengthening its export capabilities in the Middle East, having already established a footprint in Asia and South America. The company aims to meet increasing overseas demand by enhancing its production facilities. This move is not just about entering a new market; it signifies L&C BIO’s approach to solidifying its position in the global regenerative medicine industry.
The company announced on the 14th that Re2O has secured import approval from the UAE Drug Establishment (EDE). L&C BIO plans to collaborate with local medical device companies to build a robust network of medical professionals, thereby establishing the UAE as a focal point for its Middle East operations.
Understanding Re2O: The Innovative Skin Booster
Re2O is a cutting-edge product derived from an extracellular matrix (ECM) made from acellular human dermal matrix (hADM). This matrix is crafted by removing cellular elements from donated human skin and processing them into fine particles. The product harnesses essential structural characteristics and compositional elements found in human skin, particularly collagen, which is vital for improving skin texture, elasticity, and pore appearance.
L&C BIO has already found success in markets like Japan, Singapore, and Mongolia with Re2O. More recently, the product received Class 4 medical device approval in Thailand and has secured similar approval in Peru. Additionally, the company inked an exclusive supply agreement with a partner in the United States, showcasing its commitment to expanding its global presence.
Plans for Increased Production Capacity
To meet the anticipated demand in both existing and new markets, L&C BIO plans to significantly ramp up its production capacity. Currently capable of producing about 80,000 units per month, the company aims to increase this number to over 150,000 units by the end of the year. In the mid-to-long term, there are plans to establish a new manufacturing plant in Dongtan to further boost production capabilities.
The overall goal for L&C BIO is to not only enhance its production but also to broaden its distribution network to facilitate higher export volumes and sales internationally. A company official emphasized the strategic importance of the UAE import approval, stating that it lays a firm foundation for their entry into the Middle Eastern market. Moving forward, L&C BIO intends to forge stronger alliances with local partners and medical professionals, thereby creating a stable supply chain to meet market needs effectively.
In summary, as L&C BIO takes significant steps to enter the Middle East with its Re2O product, it positions itself for expansive growth and a stronger international presence in the field of regenerative medicine.